Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Cuts Target Price to $16
Pediatrix Medical Group Analyst Ratings
Truist Securities Maintains Hold on Pediatrix Medical Group, Lowers Price Target to $16
Hold Rating on Pediatrix Medical Group Amid Mixed Birth Rate Trends and Payer Mix Shifts
Analysts Offer Insights on Healthcare Companies: Icon (ICLR), Pediatrix Medical Group (MD) and Ultragenyx Pharmaceutical (RARE)
Mizuho Securities Maintains Pediatrix Medical(MD.US) With Hold Rating, Raises Target Price to $18
UBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $18.5
Pediatrix Medical Group Analyst Ratings
Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Raises Target Price to $18
Analysts Conflicted on These Healthcare Names: Insmed (INSM) and Pediatrix Medical Group (MD)
UBS Maintains Pediatrix Medical(MD.US) With Hold Rating, Raises Target Price to $18.5
Hold Rating for Pediatrix Medical Group Amid Mixed Birth Trends and Uncertain Payer Mix Sustainability
Pediatrix Medical Price Target Cut to $15.00/Share From $16.00 by Truist Securities
Truist Financial Maintains Pediatrix Medical(MD.US) With Hold Rating, Cuts Target Price to $15
Pediatrix Medical Initiated at Outperform by Macquarie
Pediatrix Medical Group Analyst Ratings
Macquarie Upgrades Pediatrix Medical(MD.US) to Buy Rating, Cuts Target Price to $18
Whit Mayo Maintains Hold Rating on Pediatrix Medical Group Amid Mixed Growth Signals and Policy Concerns
Mizuho Securities Maintains Pediatrix Medical(MD.US) With Hold Rating, Announces Target Price $15
Pediatrix Medical Price Target Raised to $15.00/Share From $13.00 by Mizuho